Anosmia, Asymptomatic COVID-19, COVID-19 Respiratory Infection, Healthy, Influenza, PASC Post Acute Sequelae of COVID 19
Conditions
Brief summary
The purpose of this study is to learn more about how to better track smell recovery in people who have been infected with the SARS-CoV-2 virus (which causes COVID-19). Many people who have been infected by this virus develop changes in their sense of smell (olfaction). We are interested in measuring smell function objectively via smell cards that test odor intensity, identification, and discrimination. Objective and precise olfactory testing that can be performed in the convenience of one's home will help identify people with smell loss after infection by SARS-CoV-2. We will use results from this test to better understand the relationship between SARS-CoV-2 infection and recovery of olfactory function and to learn whether the AROMHA longitudinal smell test is a reliable olfactory function tracking tool to quantify smell loss in the context of COVID infection. These results may inform the design of therapeutic clinical trials to accelerate the recovery of smell function.
Interventions
DEVICEAROMHA Longitudinal Smell Test
The AROMHA Longitudinal Smell Test is a self-administered, at-home smell test intended for use as a screening test by asymptomatic individuals to help prevent exposure to and spread of SARS-CoV-2, the virus that causes COVID-19, through a serial testing approach. The device consists of six versions of a smell card, each containing three unique odors.
Sponsors
Massachusetts General Hospital
National Institute on Deafness and Other Communication Disorders (NIDCD)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
Yes
Inclusion criteria
For anosmic patients/healthy controls: Inclusion criteria 1. Known anosmia (for anosmic patients only) 2. Age greater than or equal to 18 3. Access to phone, tablet or computer connected to the internet.
Exclusion criteria
1\. Known odor-evoked adverse effects, e.g. asthma. For asymptomatic participants: Inclusion criteria 1. No symptoms of COVID infection at the time of enrollment. 2. Age greater than or equal to 18 3. Access to phone, tablet or computer connected to the internet.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Aromha Longitudinal Smell Test | 12 weeks | The Aromha Smell Test is a battery of 18 odors across 6 smell cards. The subject smells each of the 3 scents per card to determine smell intensity, identification, and discrimination. Increased number of correct responses indicates better sense of smell. We will evaluate previously diagnosed anosmic patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Brief Smell Identification Test (BSIT) | 12 weeks | The BSIT is a battery of 12 odors with a score range from 0-12. Higher scores indicate a better sense of smell. We will evaluate previously diagnosed anosmic patients and healthy asymptomatic controls. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORMark W Albers, MD PhD
Massachusetts General Hospital
Outcome results
None listed